Skip to content

To explore the mechanism of NF-?B signaling pathway on diabetic peripheral neuropathy by using the method of

To explore the mechanism of NF-?B signaling pathway on diabetic peripheral neuropathy by using the method of

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005365
Enrollment
Unknown
Registered
2021-12-02
Start date
2021-11-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic peripheral neuropathy

Interventions

Experimental group:Basic treatment and routine nursing of diabetic peripheral neuropathy + needle clubbing therapy
The control group:Basic treatment and routine nursing of diabetic peripheral neuropathy

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75; 2. Inpatients meeting the diagnostic criteria for diabetes; 3. Meet the diagnostic criteria for DPN in the 2017 Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes; 4. Blood glucose control was stable for more than 2 weeks under hypoglycemic drugs and insulin treatment: FPG=8mmol/L, 2hPG=11mmol/L, and HbA1c= 8%; 5. Self-care, normal thinking, capable of language communication; 6. Those who voluntarily participate in the study and sign the informed consent; 7. Patients who had been in the Department of Endocrinology of The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine for =4 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients with damaged skin integrity at acupoint selection and pestle site, dermatitis, allergy and other skin diseases, or skin allergy to metal; 2. Ketosis and ketoacidosis; 3. Acute infectious diseases; 4. Varicose veins or edema of lower limbs; 5. After lower limb vascular surgery; 6. Complicated with serious primary diseases of heart, liver, kidney and hematopoietic system and mental diseases; 7. Severe visual impairment or blindness; 8. Cancer patients; 9. Pregnant patients.

Design outcomes

Primary

MeasureTime frame
Tumor necrosis factor -a;Interleukin-1 ß;Clinical Symptom Integral Table;Interleukin-6;

Countries

China

Contacts

Public ContactWen Jun
378111499@qq.com18980656128

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026